As the world goes to war with COVID-19, the U.S. is ripping open the purse strings to fund mobilization against both the coronavirus and the economic devastation it’s causing.
Randomized trials of the broad-spectrum antiviral favipiravir, marketed as an anti-influenza treatment by Fujifilm Holdings Corp., have shown "obvious efficacy" against COVID-19, according to Zhang Xinmin, head of the China National Center for Biotechnology Development.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Canon Medical, Quidel.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ambu, ATTC, Biointellisense, Biomerica, Bio-Techne, Centogene, Clinical Laserthermia Systems, Dover, Em-tec, Llamasoft, MeMD, Myriad Genetics, Oxford Nanopore Technologies, Pacific Biosciences of California, Parallax Health Sciences, Qiagen, Rewalk Robotics, Startx, Tomi Environmental Solutions, Tabula Rasa Healthcare, Windgo.
With the high need for ventilators in the face of COVID-19, Ventec Life Systems, of Bothell, Wash., is stepping up with its multifunction ventilator, known as VOCSN, for ventilation, oxygen, cough, suction and nebulization.
Google sister company Verily Life Sciences LLC has been under an unprecedented amount of scrutiny since it was promoted over the weekend by President Donald Trump as responsible for a nationwide information and testing program for the emerging novel coronavirus.
BEIJING – One day after the U.S. began the first human trial of an mRNA vaccine candidate for COVID-19 on March 16, China said Tuesday evening that it had approved the first clinical trial of a vaccine candidate developed by domestic researchers.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alpine, Biohaven, Pharnext, Rhythm, Sage, Synairgen.
RSS
